Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy

Abravan, A.; Price, Gareth J; Banfill, Kathryn; Marchant, T.; Craddock, M.; Wood, Joseph; Aznar, Marianne C.; McWilliam, A.; Herk, Marcel van; Faivre-Finn, Corinne

doi:10.3389/fonc.2022.934369

Cited by 11 publications

(3 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the use of MRI is recognized as having its disadvantages, including high cost, long image-acquisition time, and limited availability. Until these challenges can be addressed, its use in cardio-oncologic populations will likely remain limited to those in whom echocardiographic assessments are of poor quality or inconclusive [45][46][47][48][49][50][51][52][53][54].…”

Section: Discussionmentioning

confidence: 99%

CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Nardone,

Belfiore,

De Chiara

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Nardone,

Belfiore,

De Chiara

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Radiation therapy for lung cancer raises concerns about RIHD, which affects various parts of the heart, including the coronary arteries, myocardium, heart valves, and the pericardial sac [ 45 , 46 ]. It is crucial to be aware that conditions such as severe rheumatic mitral valve stenosis (MVS) and aortic regurgitation might mimic lung cancer symptoms, with perihilar masses and mediastinal lymphadenopathy sometimes being solely the result of hemodynamic changes and focal lymphedema.…”

Section: Reviewmentioning

confidence: 99%

The Interplay Between Cardiovascular Disease and Lung Cancer

Katic,

Choi,

Diaz Saravia

et al. 2024

Cureus

View full text Add to dashboard Cite

Cardiovascular disease (CVD) and lung cancer are among the leading causes of mortality worldwide, with a significant interplay that complicates patient management and treatment outcomes. This review explores the complex relationship between various forms of CVD - such as coronary artery disease, heart failure (HF), arrhythmias, and valvular heart disease - and lung cancer. Shared risk factors, including smoking, aging, and chronic inflammation, contribute to the co-occurrence of these conditions. Additionally, treatments for lung cancer, particularly chemotherapy and radiation therapy, can exacerbate CVD, necessitating a multidisciplinary approach to patient care. We delve into specific CVD-related impacts on lung cancer prognosis and vice versa, examining mechanisms, clinical outcomes, and management strategies. Our findings highlight the need for integrated care involving oncologists, cardiologists, and other healthcare providers to optimize treatment plans and improve patient outcomes. Emphasizing comprehensive cardiovascular risk management in lung cancer patients, we advocate for further research to deepen our understanding and develop novel therapeutic approaches, ultimately enhancing the quality of life and survival rates in patients suffering from both CVD and lung cancer.

show abstract

“…This research is a qualitative study situated within the RAPID-RT study, designed to test the use of rapid learning of RWD to improve patient outcomes in lung cancer survival. 7 Generally, participants perceived the rapidlearning approach as having the capability to foster development in radiotherapy practice by potentially offering evidence to address existing knowledge gaps. There was a consensus among interviewees that rapid learning would complement RCTs rather than replace them, as RWD is heterogeneous (unlike well-defined control trials), with the potential for bias or uncontrolled confounding factors.…”

mentioning

confidence: 99%

Embracing rapid learning in radiotherapy: feasible and acceptable with stakeholder corroboration

Poole

2024

bmjonc

View full text Add to dashboard Cite

Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy

Cited by 11 publications

References 85 publications

CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

The Interplay Between Cardiovascular Disease and Lung Cancer

Embracing rapid learning in radiotherapy: feasible and acceptable with stakeholder corroboration

Contact Info

Product

Resources

About